Fig. 6.

Clinical-stage antibodies with positively charged CDRs have increased risk for poor biophysical properties. Logistic regression analysis of the relationship between CDR net charge (pH 7.4) and the percentage of clinical-stage mAbs with <2 biophysical flags. Each mAb was assigned up to 10 biophysical flags based on previously reported measurements of antibody specificity, self-association, hydrophobicity and aggregation (Jain et al., 2017). (A,B) Regression analysis between CDR net charge and the percentage of clinical-stage mAbs with <2 biophysical flags using (A) ten or (B) four biophysical flags. The number of mAbs in each bin is reported above each bar. Receiver operating characteristic curve analysis is also reported in terms of the area under the curve (AUC) values.